Zacks Research Raises Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Zacks Research lifted their FY2024 earnings estimates for Gilead Sciences in a research report issued to clients and investors on Monday, November 4th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $3.73 per share for the year, up from their previous forecast of $3.72. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2025 earnings at $1.72 EPS, FY2025 earnings at $7.18 EPS, Q2 2026 earnings at $1.82 EPS and FY2026 earnings at $7.54 EPS.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis.

A number of other research firms have also recently weighed in on GILD. Robert W. Baird increased their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday. Piper Sandler lifted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday. Truist Financial increased their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Royal Bank of Canada upped their price target on shares of Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a report on Thursday. Eleven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $90.05.

Gilead Sciences Stock Performance

GILD stock opened at $97.90 on Thursday. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.32. The stock has a market capitalization of $121.88 billion, a price-to-earnings ratio of 119.39, a PEG ratio of 3.13 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock’s fifty day moving average is $84.58 and its two-hundred day moving average is $74.67.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in Gilead Sciences in the third quarter worth about $25,000. Valued Wealth Advisors LLC boosted its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. CarsonAllaria Wealth Management Ltd. grew its position in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 238 shares during the period. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the second quarter valued at $33,000. Finally, Cedar Wealth Management LLC grew its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,437 shares of company stock valued at $5,374,825 over the last three months. 0.29% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.